U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. K2 Trading Inc. - 635768 - 11/07/2022
  1. Warning Letters

WARNING LETTER

K2 Trading Inc. MARCS-CMS 635768 —


Delivery Method:
VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED
Product:
Food & Beverages

Recipient:
Recipient Name
Mr. Heon Jung Og
Recipient Title
President & Owner
K2 Trading Inc.

140 Hobart Street
Hackensack, NJ 07601
United States

Issuing Office:
Division of Northeast Imports

United States


WARNING LETTER

Re: CMS # 635768

Dear Mr. Heon Jung Og:

On May 4, 2022 to May 25, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of K2 TRADING INC. located at 140 Hobart Street, Hackensack, NJ 07601. We also conducted an inspection on February 19, 2021 to March 9, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.

The FSVP regulation requires that importers perform certain risk-based activities to verify that human and/or animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at: https://www.fda.gov/food/food-safety-modernization-act-fsma/fsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.

During the most recent inspection, you provided FSVP records for dried seaweed (green lavar) imported from (b)(4), located the (b)(4); wheat flakes (sujebi) imported from (b)(4), located in (b)(4); and boiled royal fern imported from (b)(4), located in (b)(4). Also during this inspection, the investigator provided you with a list of imported foods and foreign suppliers imported by you between May 1, 2021 and April 30, 2022. You identified a “No FSVP” in the “No FSVP” column of the list of imported foods and foreign suppliers, acknowledging that your firm did not develop an FSVP for some of the foods listed. Specifically, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import:

  • Korean rice cake imported from (b)(4), located in (b)(4).
  • Caramel imported from (b)(4), located in (b)(4).
  • Malt powder imported from (b)(4), located in (b)(4).
  • Glutinous rice flour imported from (b)(4), located in (b)(4).
  • Rice flour imported from (b)(4), located in (b)(4).

Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.

At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on May 25, 2022.

Your significant violations of the FSVP regulation are as follows:

You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for the following foods:

  • Korean rice cake imported from (b)(4), located in (b)(4).
  • Caramel imported from (b)(4), located in (b)(4).
  • Malt powder imported from (b)(4), located in (b)(4).
  • Glutinous rice flour imported from (b)(4), located in (b)(4).
  • Rice flour imported from (b)(4), located in (b)(4).

The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.

This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http://www.accessdata.fda.gov/cms_ia/ialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).

You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVPs, records to demonstrate implementation of your FSVPs), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.

Please send your reply to Food and Drug Administration, Attention: David Trent-Carlson, Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLRESPONSES@fda.hhs.gov. Please also cc (carbon copy) David.Trent-Carlson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Trent-Carlson via email at David.Trent-Carlson@fda.hhs.gov. Please reference CMS # 635768 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.

Sincerely,

/S/

Anna M. Alexander

Acting Program Division Director

Division of Northeast Imports

Back to Top